Table 4.
Radiotracer | Clinical Trials | Parameter | Mechanism of Localization | Strength/Weakness | References | |
---|---|---|---|---|---|---|
Radiolabeled Antibiotics | 99mTc-ciprofloxacin | Yes | Inhibition of DNA Synthesis | Bacterial DNA gyrase | High sensitivity (85.4–97.2%), ciprofloxacin already used in DFI treatment | [133,134,135,136] |
Low specificity (66.7–81.7%), antibiotic resistant bacteria | ||||||
18F-fluoropropyl-trimethoprim | No | Inhibition of Folic Acid Synthesis | Inhibition of thymidine biosynthesis | Low background, high uptake in bacteria, detect inflammation from soft tissue infection vs sterile inflammation | [167] | |
Antibiotic resistant bacteria | ||||||
99mTc-sulfonamides (pertechnetate, sulfadiazine) | No | Inhibition of Folic Acid Synthesis | Broad spectrum antibiotics, uptake in bacterial and fungal infections | [155] | ||
Antibiotic resistant bacteria | ||||||
99mTc-vancomycin | No | Inhibition of bacterial cell wall synthesis | Binds to D-ala-D-ala lipid moiety | Specific for gram positive organisms | [137,138,139] | |
Not specific for gram negative organisms Antibiotic resistant bacteria | ||||||
Radiolabeled Sugars | 18F-FDS | Yes | Bacteria-Specific Glucose Sources for Carbohydrate Metabolism | Bacterial Metabolic Substrate | Antibiotic treatment monitoring, used in humans | [140,141] |
Uptake by Enterobacteriaceae in the human gut | ||||||
18F-FAG | No | Sorbitol analogue utilized only by bacteria | Selective accumulation in E. coli, rapid accumulation, can differentiate infection from sterile inflammation, shows promise for monitoring response to treatment, small molecule | [142] | ||
Not applied clinically | ||||||
18F-maltohexose | No | Bacterial-specific maltodextrin transporter | Can discriminate between live bacteria, metabolically inactive bacteria, and sterile inflammation | [143] | ||
Poor signal-to-noise ratios, Not applied clinically | ||||||
6′′-18F-fluoromaltotriose | No | Bacterial-specific maltodextrin transporter | 2nd Gen, improved signal-to-noise ratio, bacterial-selective uptake in vitro and in vivo | [144,145] | ||
Not applied clinically | ||||||
Amino Acid Uptake | D-[methyl-11C] methionine | No | Bacterial Cell Wall Synthesis | Incorporation into the peptidoglycan | Distinguish sterile inflammation from infection in both gram—and gram +, broad sensitivity | [146,147] |
Not applied clinically | ||||||
D-5-[11C] glutamine | No | Incorporation into the peptidoglycan | Highly specific, high sensitivity for gram +, no uptake in sterile inflammation, fast clearance | [148] | ||
Corroborating studies needed, not yet applied clinically | ||||||
Vitamin Uptake | 124I-fialuridine (FIAU) | Yes | Endogenous TK enzyme of pathogenic bacteria | Trapped in the cell after phosphorylation | Reduced uptake in the presence of metal artifacts, | [154,168,169] |
More clinical studies needed to assess clinical efficacy | ||||||
111In-biotin | No | Production of Fatty Acid | Bacterial growth factor | Essential growth factor for S. aureus | [149] | |
Corroborating in vivo studies needed to assess clinical relevance | ||||||
99mTc-PAMA | No | Vitamin B12 Metabolism | Vitamin B12 derivative that accumulates in rapidly proliferating cells | High uptake in Gram + and Gram - | [150] | |
Not applied clinically | ||||||
18F or 3H-PABA | No | Folic Acid Synthesis | Inhibition of Thymidine Synthesis | Accumulation in MRSA and other resistant organisms | [151] | |
In vivo studies needed | ||||||
Polyclonal Antibodies | 64Cu-NODAGA | No | Membrane protein binding of polyclonal antibody | Microbe-specific membrane polyclonal antibody binding | Particular to a specific microbe | [164,165] |
Slow accumulation time | ||||||
Siderophores | 68Ga-FOXE | No | Iron Transport | Accumulation of Siderophores in the cell | High uptake in S. aureus and fungi | [160,161,162] |
Not used in DFI model | ||||||
Immunoscintigraphy | 99mTc-sulesomab | Yes | WBC migration to infectious foci | Binds to antigen-90 on WBC membranes | Ease of preparation? Not sure about this | [63,71] |
Dependent upon host response, expensive, limited availability | ||||||
99mTc-Besilesomab | Binds to antigen-95 on granulocytes and their precursors | Ease of preparation, good sensitivity and specificity | [63] | |||
Dependent upon host response, expensive, limited availability |
Table adapted from Ankrah et al. (2018) [131].